Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy
Open accessThe DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index; 7 of the 10 sources its claims cite were checked for support.
Abstract
BACKGROUND: Precision oncology seeks to integrate multiple layers of data from a patient's cancer to effectively tailor therapy. Conventional chemotherapies are sometimes effective but accompanied by adverse events, warranting the identification of a biomarker of chemosensitivity. OBJECTIVE: Identify an mRNA biomarker that predicts chemosensitivity across solid tumor subtypes. METHODS: We performed a pan-solid tumor analysis integrating gene expression and drug sensitivity profiles from 3 cancer cell line datasets to identify transcripts correlated with sensitivity to a panel of chemotherapeutics. We then tested the ability of an mRNA biomarker to predictive clinical outcomes in cohorts of patients with breast, lung, or ovarian cancer. RESULTS: Expression levels of several mRNA transcripts were significantly correlated with sensitivity or resistance chemotherapeutics in cancer cell line datasets. The only mRNA transcript significantly correlated with sensitization to multiple classes of DNA-damaging chemotherapeutics in all 3 cell line datasets was encoded by Schlafen Family Member 11 (SLFN11). Analyses of multiple breast, lung, and ovarian cancer patient cohorts treated with chemotherapy confirmed SLFN11 mRNA expression as a predictive biomarker of longer overall survival and improved tumor response. CONCLUSIONS: Tumor SLFN11 mRNA expression is a biomarker of sensitivity to an array of DNA-damaging chemotherapeutics across solid tumor subtypes.
Overview
CoChat Summary
TL;DR
This pan-cancer analysis identified SLFN11 mRNA as the only transcript consistently associated with sensitivity to multiple classes of DNA-damaging chemotherapeutics across three cancer cell line datasets. Clinical cohort analyses in breast, lung, and ovarian cancer supported SLFN11 mRNA as a biomarker of better survival and/or better response to chemotherapy.
Key findings
- Across CTRP, GDSC, and NCI60, Pearson correlations were computed for 2,020,930 gene-drug combinations using 27, 17, and 47 chemotherapeutics and 18,988, 17,737, and 25,675 transcripts, respectively; 13,458 genes were shared across all 3 datasets.
- SLFN11 was the only mRNA transcript significantly correlated with sensitization to multiple classes of DNA-damaging chemotherapeutics in all 3 cell line datasets, and was the only transcript correlated with sensitivity to at least half of tested drugs in 4/5 classes in ≥2 databases.
- In clinical data, high SLFN11 expression was associated with improved outcomes in selected chemotherapy-treated cohorts: breast cancer HR = 4.32, p = 0.017; one lung cancer HR = 3.72, p = 0.031 and another lung dataset HR = 2.29, p = 0.057; ovarian cancer HR = 1.79, p = 0.05.
- In treatment-naïve response cohorts, patients with complete response had higher baseline SLFN11 expression: 115 breast cancer patients, p = 0.045; 75 ovarian cancer patients, p = 0.057.
Methods
- Pan-solid tumor correlation analysis integrating transcriptomic and drug sensitivity data from CTRP (860 cell lines, 481 drugs), GDSC (1,065 cell lines, 266 drugs), and NCI60 (60 cell lines, 783,538 compounds and drugs), limited to solid tumor lineages.
- Correlated all individual mRNAs with drug sensitivity measures (AUC or IC50) using Pearson correlations; genes were selected when R > 0.2 in >50% of drugs in a chemotherapy class in ≥2/3 databases.
- Validated SLFN11 in clinical GEO datasets (GSE37751, GSE29013, GSE37745, GSE17260, GSE32646, GSE63885) using median split survival analyses, plus response comparisons by t-test for breast and ovarian cohorts.
Limitations
- The paper states that some clinical datasets had limited microarray platforms without SLFN11 probes and were therefore excluded.
- Several reported clinical associations were based on small or statistically limited samples (for example, the ovarian response cohort of 75 patients; stated in the paper).
- Evident from the text: the study is largely retrospective and correlative, so it supports association rather than direct causal proof of SLFN11’s predictive role.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig 4 Patients with tumors highly responsive to chemotherapy have high SLFN11 transcript levels. Z-score normalized RNA expression and tumor response data were obtained for primary breast and ovarian tumors from 2 datasets containing information from 115 breast cancer patients (A) and 75 ovarian cancer patients (B) treated with neoadjuvant chemotherapy. Breast cancer patients were divided into patients who had a pathologic Complete Response after chemotherapy (pCR), to those that did not (non-pCR), and SLFN11 expression was compared by Student t-test with Welch’s correction. Ovarian cancer patients were divided into patients who were highly sensitive (HS; defined as DFS>732 days according to [15]) or not (non-HS), and analyzed as above.](https://figures.cochat.ai/paper-figures/0eb6f6a00a70401f9ab6f9adfff5f5b7/integrated-pan-cancer-gene-expression-and-drug-sensitivity-analysis-reveals-figure-4.jpg)
Verification
Claims the paper makes
7 Valid · 0 Not valid · 1 Not checked · 20 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In two datasets of 55 and 196 non-small-cell lung cancer patients [11, 12], there was no significant differences in OS between patients with high vs. low SLFN11 expression (HR = 1.60 and 1.16, p = 0.348 and 0.368, respectively) (Fig 3B and 3C).”
§ Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy > Results > SLFN11 mRNA expression is prognostic of improved patient outcome following adjuvant chemotherapy
What the sources say
- Supportedcites [11] Y Xie, 2011, Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients., Clinical cancer research: an official journal of the American Association for Cancer Research source
The citation is attached to the identification of the datasets, not to the citing authors’ SLFN11 analysis in Fig. 3B–C. The Results section (page not available) identifies this paper’s FFPE dataset as 55 NSCLC patients; the other citation accompanies the 196-patient dataset. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [12] J Botling, 2013, Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation., Clinical cancer research: an official journal of the American Association for Cancer Research source
plainn = 196- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a dataset of 61 unselected breast cancer patients [10], aggregate survival analysis showed no significant difference in overall survival (OS) between patients with high vs. low tumor SLFN11 expression (HR = 1.24, p = 0.608) (Fig 3A).”
§ Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy > Results > SLFN11 mRNA expression is prognostic of improved patient outcome following adjuvant chemotherapy
What the sources say
- Partly supportedcites [10] W Tang, 2018, Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival, Genome medicine sourceExperimental — accuracy not yet measured
The Results section on proteomic profiling describes a breast-cancer dataset, but reports 65 tumors, not 61 patients. The citation is attached to the dataset description; the SLFN11 survival analysis is presented as the citing authors’ own result in Fig. 3A, so it need not appear in this source. Our copy does not establish the stated 61-patient subset or that patients were unselected. (LLM, conf=0.83)
plainn = 61- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a randomized Phase II study by Pietanza et al. showed that patients with small cell lung cancers expressing SLFN11 had improved progression-free survival (PFS) and (OS) upon treatment with the combination of a PARP inhibitor and the alkylating agent temozolomide [32].”
§ Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy > Discussion
What the sources say
- Supportedcites [32] MC Pietanza, 2018, Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer., Journal of clinical oncology: official journal of the American Society of Clinical Oncology source
The Results section reports significantly longer PFS and OS among patients with SLFN11-positive tumors treated with temozolomide/veliparib. The Discussion also states that these patients had better PFS and OS than those treated with temozolomide/placebo. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Comparison of SLFN11 transcript levels in these tumors, while statistically limited by sample size, also demonstrated a trend towards higher levels of SLFN11 expression in patients with CR vs. non-CR (p = 0.057) (Fig 4B).”
§ Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy > Results > Patients with tumors highly responsive to chemotherapy have high SLFN11 transcript levels
What the sources say
- Partly supportedcites [15] KM Lisowska, 2014, Gene expression analysis in ovarian cancer—faults and hints from DNA microarray study, Frontiers in oncology sourceExperimental — accuracy not yet measured
The Materials and Methods (Clinical samples; page unavailable) describe an ovarian-cancer cohort treated with platinum-containing regimens, and the Results (Response to chemotherapy; page unavailable) classify patients by chemotherapy response. But the clinical analyses use 72 samples, not 75, and the paper does not report a SLFN11 comparison between CR and non-CR patients or p = 0.057. (LLM, conf=0.86)
hedgedstates an associationn = 75 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“To functionally implicate SLFN11 in response to DNA-damaging chemotherapeutics (topoisomerase inhibitors, an anti-metabolite, and an alkylating agent), Li et al. demonstrated that genetic inhibition of SLFN11 expression caused chemoresistance [28].”
§ Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy > Discussion
What the sources say
- Supportedcites [28] M Li, 2018, DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs, Nat Struct Mol Biol source
The Results report that lentiviral shRNA silencing of SLFN11 significantly increased resistance in FG and 293 cells to camptothecin, mitoxantrone, gemcitabine, and chlorambucil. The Results also report that CRISPR-Cas9 abrogation of SLFN11 produced an even stronger DNA-damaging-agent resistance phenotype in those cell lines. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
14 more claims
Create a free account to see all 28 claims and to verify the 2 references still open.
- Probably not a substantial claim. 2
- It may state two separate claims as one. 7
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“observed an association between SLFN11 mRNA levels and sensitivity to topoisomerase inhibitors, but SLFN11 knockdown did not alter chemosensitivity [31].”
BackgroundIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“, dabrafenib) for the treatment of patients with BRAF-mutant melanoma [1].”
BackgroundComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051 · cited 1×
“Robust Multi-array Average (RMA)-normalized transcriptomic data and drug sensitivity data [area under the curve (AUC) and IC50] were downloaded for A) 860 cancer cell lines and 481 drugs from the Cancer Therapeutics Response Portal (CTRP) [4], B) 1,065 cancer cell lines and 266 drugs from the Genomics of Drug Sensitiv…”
MethodGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Cited by
Lheureux, S., Cristea, M. C., Bruce, J. P., Garg, S., Cabanero, M., Mantia-Smaldone, G., Olawaiye, A. B., Ellard, S. L., Weberpals, J. I., Wahner Hendrickson, A. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32554-x · Cited by 210
DNA damage induces p53-independent apoptosis through ribosome stalling
Boon, N. J., Oliveira, R. A., Körner, P.-R., Kochavi, A., Mertens, S., Malka, Y., Voogd, R., van der Horst, S. E. M., Huismans, M. A., Smabers, L. P., et al. (2024) · Science · doi:10.1126/science.adh7950 · Cited by 170
Overcoming Chemotherapy Resistance in SCLC
Herzog, B. H., Devarakonda, S. H. K., & Govindan, R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.018 · Cited by 132
Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress
Murai, J., Zhang, H., Pongor, L. S., Tang, S.-W., Jo, U., Moribe, F., Ma, Y., Tomita, M., & Pommier, Y. G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.117 · Cited by 87
“Since the initial discovery in cancer cell lines, the relevance of SLFN11 to drug sensitivities has been consolidated in various tumor models as well as in the clinic (Allison Stewart et al., 2017; Coussy et al., 2020; Deng et al., 2015; Gardner et al., 2017; Goss and Gordon, 2016; Kang et al., 2015; Lok et al., 2017;…”
BackgroundJo, U., Murai, Y., Chakka, S., Chen, L., Cheng, K. C.-C., Murai, J., Saha, L. K., Jenkins, L. M. M., & Pommier, Y. G. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015654118 · Cited by 85
“Profiling SLFN11 expression is being explored for patients to predict survival and guide therapeutic choice (8, 13, 18 – 24).”
Metadata
- Authors
- Shee, K., Wells, J. D., Jiang, A., & Miller, T. W.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Miller, Todd W.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-11-04
- Volume
- 14
- Issue
- 11
- Pages
- e0224267
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6827986
- OpenAlex
- W2983197547
- Semantic Scholar
- 1e303f743cf21b08dc8a3c1afbb5c60aa1a72c5e
- Cited by
- 43
- References
- 48
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 3 · 2022: 3 · 2021: 16 · 2020: 5
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA211869, F30CA216966, P30CA023108, R01CA200994)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- SLFN11, chemosensitivity biomarker, DNA-damaging chemotherapy, solid tumors, pan-cancer analysis, gene expression, drug sensitivity, cancer cell lines, breast cancer, lung cancer, ovarian cancer, overall survival, precision oncology
- MeSH terms
- Progression-Free Survival, Antineoplastic Agents, DNA Damage, Female, Humans, Neoplasms, Nuclear Proteins, Predictive Value of Tests, Prognosis, RNA, Messenger, Time Factors, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Survival Analysis, Drug Resistance, Neoplasm, Gene Expression Profiling, Cell Line, Tumor, Precision Medicine, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy. https://app.cochat.ai/papers/10.1371/journal.pone.0224267
- The paper
- Shee, K., Wells, J. D., Jiang, A., & Miller, T. W. (2019). Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy. PLOS ONE. https://doi.org/10.1371/journal.pone.0224267
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.